Business Wire

Mary Kay Unveils 2025 Sustainability Report, Underscoring Key Milestones Across Social, Economic, and Environmental Spheres

15.7.2025 14:00:00 CEST | Business Wire | Press Release

Share

Mary Kay Inc., a global advocate for sustainability and women’s empowerment, today announced the release of its 2025 Sustainability Report, a comprehensive overview of the company’s 2030 commitments and 2024 milestone achievements for creating positive impact around the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715989652/en/

The annual sustainability report highlights Mary Kay’s decades-long dedication to social, economic, and environmental sustainability – core pillars central to its business strategy and its purpose-driven legacy rooted in the company’s mission of “enriching women’s lives” around the world. (Photo Courtesy: Mary Kay Inc.)

The annual report highlights Mary Kay’s decades-long dedication to social, economic, and environmental sustainability – core pillars central to its business strategy and its purpose-driven legacy rooted in the company’s mission of “enriching women’s lives” around the world.

“For over 60 years, our company has championed a business model and key initiatives that empower women, help protect the planet, and model resilient communities,” said Ryan Rogers, Chief Executive Officer of Mary Kay. “This year’s report reaffirms our goals and commitments, while celebrating the measurable and meaningful impact we are creating worldwide.”

From product stewardship and biodiversity preservation to advancing women’s equality and economic inclusion, and accelerating digitalization efforts to unleash entrepreneurship, Mary Kay continues to integrate sustainability into every facet of its business. Below are key 2024 highlights:

Environmental:

  • Responsible Packaging: Reaffirmed our commitments to reducing plastic intensity, increase post-consumer recycled content (PCR), and increase recycle-ready/recyclable packaging1. For example, the bottle of Mary Kay TimeWise® Targeted-Action® Toning Lotion contains 94% PCR content.
  • Sustainable Sourcing: 93% of Roundtable on Sustainable Palm Oil (RSPO) certified Palm Oil is used by our suppliers as of 2024 and 80% of our Shea use was sourced from the Global Shea Alliance (GSA) member suppliers.
  • Water Management: 100% of the water used at our Richard R. Rogers (R3) global R&D and Manufacturing facility in Texas is treated and recycled back into the local watershed.
  • Impact Partnerships: Celebrated 37-year partnership with The Nature Conservancy (TNC) representing 100 conservation projects supported and 16-year partnership with the Arbor Day Foundation (ADF) to preserve ecosystems in Texas and around the world through 34 projects.

Social:

  • Pink Changing Lives®: $230 million USD donated in monetary and in-kind donations by Mary Kay Inc. and its four Company-sponsored foundations globally since 19962.
  • Women’s Empowerment: 600K+ women positively impacted globally through meaningful programs at the global, regional, and local levels as of 2024.
  • Future of STEM: 37 grants awarded to young women from 16 countries pursuing STEM careers and 8 grants awarded to female students through the “Madam C.J. Walker Scholarships” with The Society of Cosmetic Chemists (SCC) sponsored by Mary Kay as of 2024.
  • Impact Partnerships: Mary Kay served as a special award organization at the International Science and Engineering Fair (ISEF) in 2024.

Economic:

  • Women Powered: 63% of the global workforce at Mary Kay are female and 57% of leadership positions are held by women in our top 10 markets. 60% of our Executive team is female3.
  • Global Footprint: Mary Kay expanded into Kyrgyzstan.
  • Digitalization: Reimagined the digital selling experience through embracing digital opportunities while maintaining the hallmark of personalized service and attention our Independent Beauty Consultants (IBCs) are known for. In 2024, Mary Kay launched the “Phygital” campaign in Mexico and Brazil with Colombia to follow in 2025.
  • Advocacy: Engaged in 100+ trade associations globally on a range of policy issues from direct selling and entrepreneurship to personal care and supply chain and logistics. In Brazil, Mary Kay contributed to the G20 Employment & Education Task Force (B20) Policy Paper.

IN 2024 AND 2025, MARY KAY EARNED SIGNIFICANT RECOGNITIONS:

Mary Kay’s 2025 Sustainability Report is aligned with the United Nations Sustainable Development Goals (SDGs) and serves as a benchmark for stakeholders and partners seeking to drive collective impact.

To view the full report, visit here.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 40 markets. For over 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com. Find us on Facebook, Instagram, and LinkedIn, or follow us on X

1

Recyclable only where facilities exist.

2

While the Company has provided philanthropic support to charitable causes for many decades, official documentation began in 1996 with the founding of the Mary Kay Ash Foundation® (U.S.).

3

Women Representation and Leadership at Mary Kay (May 2025).

4

“Source Euromonitor International Limited; Beauty and Personal Care 2025 Edition, value sales at RSP, 2024 data”

View source version on businesswire.com: https://www.businesswire.com/news/home/20250715989652/en/

Contacts

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye